Pharvaris N.V. (PHVS)
Develops a pill to treat rare swelling diseases caused by excess bradykinin.
$33.65-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+68.2%
The outlook
Pharvaris trades at $33.65 with strong analyst support—14 analysts average a "Strong Buy" rating. The stock sits well above both its 50- and 200-day moving averages and sits near the upper end of its 52-week range. The average analyst price target sits roughly 40% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 14 analysts
Price trendAbove its 50- & 200-day averages
52-week range83% of the way from its 52-week low to high
Price targetAvg target +40% vs current price
Analyst price target
~12-month · 14 analysts$47.07average target+39.9% vs now
Now $33.65
Low $32.09High $73.80
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.35B
52-wk high
$36.60
52-wk low
$19.12
50-day avg
$32.43
200-day avg
$27.75
Trailing P/E
—